ClinicalTrials.gg
CompletedNCT05335005Updated Oct 17, 2024Results posted

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

A Phase 1 interventional study of MK-2060 in End-Stage Renal Disease and Kidney Failure, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed at 3 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.

Enrollment
11th of 12
12 · median 18
Started
2022
with 1 other
Phase 1
10 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 11th largest by enrollment, is one of 2 that started in 2022, is one of 10 in phase 1, and was the 8th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc as a file.
02

Study summary

MK-2060 is being developed for prevention of thrombotic complications in end-stage renal disease (ESRD). The purpose of this study is to conduct a preliminary evaluation of the safety and tolerability of MK-2060 treatment in combination with a commonly used P2Y12 receptor inhibitor, clopidogrel, in ESRD patients.

03

Conditions studied

  • End-Stage Renal Disease
  • Kidney Failure, Chronic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has End-Stage Renal Disease (ESRD) maintained on stable outpatient hemodialysis (HD) regimen at a healthcare center for > 3 months prior to dosing.
  • On HD regimen at least 3 times per week for a minimum of 3 hours per dialysis session, using a complication-free well-maintained AV fistula or AV graft.
  • Is taking clopidogrel for a minimum of 2 weeks prior to the first dosing of MK-2060 administration.
  • Has a (BMI) ≥ 18 and ≤ 45 kg/m\^2.

Exclusion criteria

Exclusion Criteria:

  • History of cancer (), including adenocarcinoma, except adequately treated nonmelanomatous skin carcinoma or carcinoma in situ of the cervix or other malignancies that have been successfully treated with appropriate follow up.
  • Has a history of deep vein thrombosis or pulmonary embolism.
  • Has a history of gastrointestinal (GI) bleeding, duodenal polyps or gastric ulcer in the last 5 years or severe hemorrhoidal bleed in last 3 months prior to screening.
  • Is positive for surface antigen or (HIV).
  • Has ongoing anticoagulant therapy or antiplatelet therapy, not including clopidogrel. Intradialytic heparin is permitted.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    MK-2060

    Participants continued their established background therapy of daily 75 mg clopidogrel for 2 weeks (days -14 to 0). Participants then continued background therapy while receiving 25 mg MK-2060 intravenous (IV) infusion on days 1, 3, 5, and 8.

    Drug: MK-2060

Interventions

  • MK-2060 administered via IV infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)

    Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically-relevant non major bleeding or major bleeding.

    Time frame: Up to approximately 104 days

  2. Number of Participants Who Experience One or More AEs

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 104 days

  3. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to approximately 8 days

Secondary outcomes

  1. Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) of MK-2060

    The AUC0-168 was defined as the area under the concentration-time curve of MK-2060 in plasma from time zero to 168 hours after administration. The Week 1 value is the extrapolated value using data up to 48 hours postdose Day 1, with the "Partial area" option in WinNonlin software using a Start time of 0 hours and an End time of 168 hours. Week 2 value included data for Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose.

    Time frame: Day 1: predose, and 1, 12, 24, and 48 hours postdose. Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose.

  2. Maximum Plasma Concentration (Cmax) of MK-2060

    Cmax was defined as the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose.

    Time frame: Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.

  3. Plasma Concentration at 168 Hours (C168) of MK-2060

    C168 was defined as the concentration of MK-2060 observed in plasma 168 hours after administration. Week 2 value included data for Day 8: 168 hours postdose.

    Time frame: Days 1 and 8: 168 hours post-dose

  4. Time to Maximum Plasma Concentration (Tmax) of MK-2060

    Tmax was defined as the time required to reach the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose.

    Time frame: Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.

  5. Terminal Half Life (t1/2) of MK-2060

    T1/2 was defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium.

    Time frame: Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.

  6. Clearance at Steady State (CLss) of MK-2060

    CLss was defined as the volume of plasma from which MK-2060 was eliminated per unit time following administration, once at steady state.

    Time frame: Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.

  7. Apparent Volume of Distribution at Steady State (Vss) of MK-2060

    Vss was defined as the volume of plasma that would be necessary to contain the total amount of administered MK-2060 at the same concentration that MK-2060 was observed in the blood plasma after reaching steady state.

    Time frame: Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.

  8. Time to Hemostasis Following MK-2060 Treatment

    Time to hemostasis is assessed by measuring the time that pressure is held from removal of dialysis catheters from the dialysis access site \[i.e., arteriovenous (AV) fistula or AV graft\] until adequate hemostasis has been obtained for both the arterial and venous sites.

    Time frame: Up to approximately 15 days

07

Results

Posted Oct 17, 2024

Participant flow

Participant flow — Overall Study
MilestoneMK-2060
Started12
Completed11
Not completed1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryNumber of Participants Who Experience One or More Bleeding Related Adverse Events (AE)

Bleeding related AEs include any sign or symptom of bleeding, even if not requiring intervention by a medical/healthcare professional, as well as clinically-relevant non major bleeding or major bleeding.

Time frame:
Up to approximately 104 days
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)
ParticipantsMK-2060
Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE)0
PrimaryNumber of Participants Who Experience One or More AEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 104 days
Reported as:
Count of participants · Participants
Number of Participants Who Experience One or More AEs
ParticipantsMK-2060
Number of Participants Who Experience One or More AEs6
PrimaryNumber of Participants Who Discontinue Study Intervention Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to approximately 8 days
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Intervention Due to an AE
ParticipantsMK-2060
Number of Participants Who Discontinue Study Intervention Due to an AE0
SecondaryArea Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) of MK-2060

The AUC0-168 was defined as the area under the concentration-time curve of MK-2060 in plasma from time zero to 168 hours after administration. The Week 1 value is the extrapolated value using data up to 48 hours postdose Day 1, with the "Partial area" option in WinNonlin software using a Start time of 0 hours and an End time of 168 hours. Week 2 value included data for Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose.

Time frame:
Day 1: predose, and 1, 12, 24, and 48 hours postdose. Day 8: predose, and 1, 12, 24, 48, 96, and 168 hours postdose.
Reported as:
Geometric mean · hour*nmol/L
Area Under the Concentration-Time Curve From 0 to 168 Hours (AUC0-168) of MK-2060
hour*nmol/LMK-2060
Week 12040 ± 27.5
Week 29060 ± 40.5
SecondaryMaximum Plasma Concentration (Cmax) of MK-2060

Cmax was defined as the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose.

Time frame:
Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Reported as:
Geometric mean · nmol/L
Maximum Plasma Concentration (Cmax) of MK-2060
nmol/LMK-2060
Week 129.7 ± 19.9
Week 287.6 ± 24.2
SecondaryPlasma Concentration at 168 Hours (C168) of MK-2060

C168 was defined as the concentration of MK-2060 observed in plasma 168 hours after administration. Week 2 value included data for Day 8: 168 hours postdose.

Time frame:
Days 1 and 8: 168 hours post-dose
Reported as:
Geometric mean · nmol/L
Plasma Concentration at 168 Hours (C168) of MK-2060
nmol/LMK-2060
Week 143.1 ± 26.7
Week 234.3 ± 66.2
SecondaryTime to Maximum Plasma Concentration (Tmax) of MK-2060

Tmax was defined as the time required to reach the maximum concentration of MK-2060 observed in plasma after administration. Week 2 value included data for Day 8: predose and 1, 12, 24, 48, 96, and 168 hours postdose.

Time frame:
Day 1: predose, and 1, 12, and 48 hours postdose. Day 8: predose, and 1, 12, and 24 hours postdose; and once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Reported as:
Median · Hours
Time to Maximum Plasma Concentration (Tmax) of MK-2060
HoursMK-2060
Week 11.03 (0.75 to 1.25)
Week 21.07 (0.90 to 12.00)
SecondaryTerminal Half Life (t1/2) of MK-2060

T1/2 was defined as the time required to divide the MK-2060 plasma concentration by two after reaching pseudo-equilibrium.

Time frame:
Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Reported as:
Geometric mean · Hours
Terminal Half Life (t1/2) of MK-2060
HoursMK-2060
Terminal Half Life (t1/2) of MK-2060402 ± 31.5
SecondaryClearance at Steady State (CLss) of MK-2060

CLss was defined as the volume of plasma from which MK-2060 was eliminated per unit time following administration, once at steady state.

Time frame:
Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Reported as:
Geometric mean · L/hour
Clearance at Steady State (CLss) of MK-2060
L/hourMK-2060
Clearance at Steady State (CLss) of MK-20600.0170 ± 25.6
SecondaryApparent Volume of Distribution at Steady State (Vss) of MK-2060

Vss was defined as the volume of plasma that would be necessary to contain the total amount of administered MK-2060 at the same concentration that MK-2060 was observed in the blood plasma after reaching steady state.

Time frame:
Day 8: predose, and 1, 12, and 24 hours postdose. Once daily on Days 10, 12, 15, 21, 29, 35, 49, 67, and 104.
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution at Steady State (Vss) of MK-2060
LitersMK-2060
Apparent Volume of Distribution at Steady State (Vss) of MK-20606.34 ± 33.3
SecondaryTime to Hemostasis Following MK-2060 Treatment

Time to hemostasis is assessed by measuring the time that pressure is held from removal of dialysis catheters from the dialysis access site \[i.e., arteriovenous (AV) fistula or AV graft\] until adequate hemostasis has been obtained for both the arterial and venous sites.

Time frame:
Up to approximately 15 days
Reported as:
Mean · Minutes
Time to Hemostasis Following MK-2060 Treatment
MinutesMK-2060
Time to Hemostasis Following MK-2060 Treatment11.0 (6.97 to 15.1)

Adverse events

Collected over Run-in (Clopidogrel 75 mg) arm: Approximately 14 days MK-2060 25 mg IV/Clopidogrel 75 mg arm: Up to approximately 108 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in (Clopidogrel 75 mg)0/12 (0%)0/12 (0%)1/12 (8.3%)
MK-2060 25 mg IV/Clopidogrel 75 mg0/12 (0%)3/12 (25%)5/12 (41.7%)
Most frequent serious events
Most frequent serious events
EventRun-in (Clopidogrel 75 mg)MK-2060 25 mg IV/Clopidogrel 75 mg
OsteomyelitisInfections and infestations0/121/12
PneumoniaInfections and infestations0/121/12
Staphylococcal sepsisInfections and infestations0/121/12
Arteriovenous fistula site complicationInjury, poisoning and procedural complications0/121/12
SyncopeNervous system disorders0/121/12
DyspnoeaRespiratory, thoracic and mediastinal disorders0/121/12
Most frequent other events
Most frequent other events
EventRun-in (Clopidogrel 75 mg)MK-2060 25 mg IV/Clopidogrel 75 mg
ArthralgiaMusculoskeletal and connective tissue disorders1/121/12
Back painMusculoskeletal and connective tissue disorders1/120/12
HeadacheNervous system disorders0/121/12
Metabolic encephalopathyNervous system disorders0/121/12
AgitationPsychiatric disorders0/121/12
Renal hypertensionRenal and urinary disorders0/121/12
Cold sweatSkin and subcutaneous tissue disorders0/121/12
HypotensionVascular disorders0/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MK-2060
Mean57.3 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)MK-2060
Female0
Male12
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MK-2060
Hispanic or Latino1
Not Hispanic or Latino11
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MK-2060
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American7
White5
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Genesis Clinical Research, LLC ( Site 0003)
    Tampa, Florida 33603, United States
  • Hadassah Medical Center-Clinical Reaserch Unit ( Site 0002)
    Jerusalem, 9112001, Israel
  • ARENSIA Exploratory Medicine-Clinical Nephrology Hospital "Carol Davila" ( Site 0001)
    București, Bucuresti 010701, Romania
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Feb 2023, 8 months.

Results were first posted in Oct 2024, 1 year 8 months after primary completion.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 8 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2022
First posted
Apr 19, 2022
StartActual
May 30, 2022
Primary completionActual
Feb 14, 2023
CompletionActual
Feb 14, 2023
Results first posted
Oct 17, 2024
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05335005
Responsible party
Sponsor
First posted
Apr 19, 2022
Start date
May 30, 2022
Primary completion
Feb 14, 2023
Completion
Feb 14, 2023
Results posted
Oct 17, 2024
Last update
Oct 17, 2024

Study contacts

Medical Director
study director · Merck Sharpe & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-2060

Start the discussion